Compare JEOL Ltd. with Similar Stocks
Dashboard
1
With a fall in Net Sales of -39.06%, the company declared Very Negative results in Jun 26
- The company has declared negative results for the last 2 consecutive quarters
- DEBT-EQUITY RATIO (HY) Highest at -12.75 %
- INVENTORY TURNOVER RATIO(HY) Lowest at 1.12 times
- NET SALES(Q) Lowest at JPY 24,465 MM
Stock DNA
Pharmaceuticals & Biotechnology
JPY 430,350 Million (Mid Cap)
12.00
NA
0.00%
-0.09
15.40%
2.97
Revenue and Profits:
Net Sales:
24,465 Million
(Quarterly Results - Jun 2026)
Net Profit:
-1,710 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
5.34%
0%
5.34%
6 Months
21.5%
0%
21.5%
1 Year
51.69%
0%
51.69%
2 Years
39.57%
0%
39.57%
3 Years
51.79%
0%
51.79%
4 Years
35.0%
0%
35.0%
5 Years
-20.45%
0%
-20.45%
JEOL Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
11.03%
EBIT Growth (5y)
34.62%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.20
Sales to Capital Employed (avg)
1.28
Tax Ratio
25.06%
Dividend Payout Ratio
30.52%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
26.44%
ROE (avg)
16.17%
Valuation key factors
Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
2.30
EV to EBIT
10.39
EV to EBITDA
8.82
EV to Capital Employed
2.57
EV to Sales
1.67
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
24.78%
ROE (Latest)
19.07%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
24,465.00
40,145.00
-39.06%
Operating Profit (PBDIT) excl Other Income
-588.00
6,981.00
-108.42%
Interest
89.00
22.00
304.55%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1,710.00
4,669.00
-136.62%
Operating Profit Margin (Excl OI)
-80.20%
144.30%
-22.45%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is -39.06% vs 10.43% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is -136.62% vs 19.84% in Jun 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
179,353.00
196,695.00
-8.82%
Operating Profit (PBDIT) excl Other Income
31,529.00
40,803.00
-22.73%
Interest
133.00
120.00
10.83%
Exceptional Items
-155.00
-12,315.00
98.74%
Consolidate Net Profit
22,097.00
18,688.00
18.24%
Operating Profit Margin (Excl OI)
145.10%
181.10%
-3.60%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is -8.82% vs 12.83% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is 18.24% vs -13.90% in Mar 2025
About JEOL Ltd. 
JEOL Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






